Blog Layout

Haemochromatosis
June 14, 2020

Haematologists do see patients with elevated iron stores (ferritin) in the clinic.

In a large proportion of patients, this issue is contributed by increase liver inflammation due to fat in the liver (fatty liver) and excess of alcohol intake. However, high iron stores can also be caused by a familial condition called haemochromatosis.


Haemochromatosis is the most common inherited disorder resulted from too much iron being absorbed and stored in the body. It affects 1 in 200 Australians of European origin.


Haemochromatosis can be entirely asymptomatic initially but if the iron overload is not addressed, it can lead to heart failure, liver failure, diabetes mellitus, joint pain, and hormonal disturbances. Symptoms tend to occur after the age of 40 but may be earlier or later. Early symptoms may include fatigue, abdominal pain and joint aches. Women develop iron overload usually after menopause due to a lack of blood loss from periods and childbirth, and increased demand of iron during pregnancy.


Haemochromatosis can easily be diagnosed by a simple blood test. Please ask your GP to request iron studies and haemochromatosis gene studies if there is any family member being diagnosed with the disease.


Not all patients with haemochromatosis gene will develop iron overload and the symptoms associated with it. However, if patients are at risk of iron overload, haemochromatosis can be managed by taking the blood out regularly (“blood letting” or venesection) given that 75% of body iron is stored in red blood cells. The blood from haemochromatosis patients can safely be used for other patients who need blood transfusion. If the venesection happens at pathology providers, hospitals and clinics, the blood will be discarded. If you have no significant medical problems, you can become a lifetime blood donor at Red Cross Lifeblood.


Patients with haemochromatosis can save multiple lives and at the same time getting the iron level maintained in a safe level. Early diagnosis and treatment prevent complications and result in a normal life expectancy.

Haematologist Dr Marsali Maclean joins Ballarat Cancer Care
February 16, 2025
Haematologist Dr Marsali Maclean joins Ballarat Cancer Care
December 3, 2024
We are pleased to announce palliative care physician Dr Russell Pearce will be joining our team in February 2025.
New haematologist  joining the Ballarat Cancer Care team
August 27, 2024
We are excited to announce Dr Tishya Indran will be joining our team as of 18th September 2024. 
4th Dose COVID-19 Vaccine for Immunocompromised Patients
March 1, 2022
The Australian Technical Advisory Group on Immunisation (ATAGI) has approved a fourth dose of a COVID-19 vaccine for people with weakened immune systems. People aged 18 years or older with weakened immune system who received a 3-dose primary course of the COVID-19 vaccine are now recommended to receive the fourth dose ≥ 3 months after their third dose. This is expected to improve protection against symptomatic infection, serious illness, or death from COVID-19 infection.
COVID-19 Vaccine Booster Shots In Our Patients With Cancer
November 8, 2021
The Government and the Medical advisory group (ATAGI) have release new recommendations last week for individuals who are severely immunocompromised in regards to the COVID-19 vaccine. These recommendations will affect some (but not all) of our patients. As always, we are happy to discuss any of the recommendations further with all of our patients.
COVID-19 Vaccination FAQs July 2021
July 20, 2021
In the last few months, I have been inundated with many questions regarding COVID-19 vaccination and blood clots from patients and other health practitioners. In this article, I have compiled these frequently asked questions.
New PBS listings!
July 2, 2021
Despite a global pandemic, new data relating to oncology treatments continues to be published, and it seems that this is increasingly translating into improved drug access here in Australia.
Astra Zeneca (AZ) vaccine safety information
March 26, 2021
In light of recent reports of clotting events following Astra Zeneca (AZ) vaccine in Europe - we have been frequently asked questions regarding the safety of AZ vaccine in patients with previous clot events and/or blood problems
February 25, 2021
Two vaccines against the coronavirus have now been approved for use in Australia, role-out of the vaccine begins this week in high-risk populations.
January 18, 2021
Dr Swe Myo Htet Consultant Haematologist MBBS, FRACP, FRCPA, MRCP
More Posts
Share by: